No Generic Available — 25 Drugs

Brand-name only drugs with no generic alternative — patent-protected.

Drugs

$72.5B

Total Spending

$5,299.08

Avg Cost/Claim

All Drugs — No Generic Available

#	Drug	Generic Name	Cost/Claim	Medicare Spending	YoY Change	Manufacturer
1	Revlimid	Lenalidomide	$12,786.00	$7.8B	-3.4%	Bristol-Myers Squibb
2	Keytruda	Pembrolizumab	$18,176.00	$7.2B	+28.6%	Merck
3	Ozempic	Semaglutide	$685.00	$5.0B	+72.5%	Novo Nordisk
4	Entresto	Sacubitril/Valsartan	$379.00	$4.8B	+18.3%	Novartis
5	Dupixent	Dupilumab	$2,819.00	$4.4B	+35.2%	Regeneron/Sanofi
6	Trulicity	Dulaglutide	$473.00	$4.2B	-4.8%	Eli Lilly
7	Biktarvy	Bictegravir/Emtricitabine/TAF	$3,746.00	$3.8B	+12.8%	Gilead
8	Pomalyst	Pomalidomide	$17,250.00	$3.3B	+4.7%	Bristol-Myers Squibb
9	Trelegy Ellipta	Fluticasone/Umeclidinium/Vilanterol	$380.00	$2.9B	+19.8%	GlaxoSmithKline
10	Januvia	Sitagliptin	$219.00	$2.7B	-12.3%	Merck
11	Jakafi	Ruxolitinib	$11,432.00	$2.7B	+11.2%	Incyte
12	Repatha	Evolocumab	$757.00	$2.6B	+24.6%	Amgen
13	Mounjaro	Tirzepatide	$673.00	$2.5B	+312.4%	Eli Lilly
14	Skyrizi	Risankizumab	$4,475.00	$2.3B	+42.8%	AbbVie
15	Rinvoq	Upadacitinib	$3,498.00	$2.3B	+56.3%	AbbVie
16	Venclexta	Venetoclax	$6,784.00	$2.2B	+18.9%	AbbVie/Genentech
17	Tagrisso	Osimertinib	$11,591.00	$2.2B	+14.5%	AstraZeneca
18	Enbrel	Etanercept	$1,726.00	$1.7B	-15.2%	Amgen
19	Vraylar	Cariprazine	$383.00	$1.7B	+26.3%	AbbVie
20	Gilenya	Fingolimod	$5,738.00	$1.4B	-14.8%	Novartis
21	Harvoni	Ledipasvir/Sofosbuvir	$24,958.00	$1.2B	-38.2%	Gilead
22	Trintellix	Vortioxetine	$278.00	$1.1B	+7.8%	Takeda
23	Fasenra	Benralizumab	$2,836.00	$987.0M	+18.6%	AstraZeneca
24	Basaglar	Insulin Glargine (biosimilar)	$130.00	$845.0M	-12.1%	Eli Lilly
25	Breztri Aerosphere	Budesonide/Glycopyrrolate/Formoterol	$305.00	$756.0M	+48.3%	AstraZeneca

Frequently Asked Questions

Most drugs without generics are still under patent protection or market exclusivity. Biologic drugs face longer exclusivity periods (12 years). Some drugs may have pending generic applications (ANDAs) at the FDA.

25 drugs tracked by Medicare Part D have no generic option, accounting for $72.5B in total spending.

Spending data comes from the CMS Medicare Part D Drug Spending Dashboard. Generic availability is determined from the FDA Orange Book, which tracks approved drug products and patent/exclusivity information.